Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Trial Profile

Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Monalizumab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Innate Pharma
  • Most Recent Events

    • 01 Oct 2019 According to an Innate Pharma media release, the Company is moving forward with the planned expansion cohorts in IO-pretreated and IO-naive R/M SCCHN patients.
    • 01 Oct 2019 According to an Innate Pharma media release, one-year survival data (n=40) of the first expansion cohort of this phase II trial evaluating monalizumab in combination with cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck were presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
    • 01 Oct 2019 Results (one-year survival data; n=40) of the first expansion cohort of this phase II trial evaluating monalizumab in combination with cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck presented in an Innate Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top